Table 2.

Baseline characteristics of patients

Variables	AD-naïve	Overall	NMD	MD	BD
	n = 80	n = 71	n = 35	n = 17	n = 19
Age (years)	59 (47–65)	53 (43–53)	53 (45–57)	56 (52–63)	47 (45–55)
Gender (n, %)
Female	42	40	19	10	11
Male	38	31	16	7	8
Education (years)	14 (12–26)	14 (12–26)	14 (12–26)	14 (12–26)	12 (12–26)
Total treated drugs (n)
ADs	0	122	71	25	26
SSRI	0	35	21	7	7
SNRI	0	27	13	7	7
NaSSA	0	32	22	5	5
TCA	0	9	4	3	2
Others	0	18	12	3	3
Mood stabilizer	0	27	10	6	11
Antipsychotics	0	22	8	3	11
Benzodiazepines	34	79	36	24	19
Dose of ADs (mg/day) imipramine equivalents	0	150 (125–175)	150 (125–175)	150 (125–175)	125 (100–150)*
Median number of treated agents per one patient
ADs	0	2 (1–2)	2 (1–2)	1 (1–2)**	1 (1–2)**
Mood stabilizer	0	0 (0–1)	0 (0–1)	0 (0–1)	1 (0–1)
Antipsychotics	0	0 (0–1)	0 (0–1)	0 (0–1)	1 (0–1)*
Benzodiazepines	0 (0–1)	1 (1–1)	1 (1–1)	1 (1–2)	1 (1–1)
Period from hospitalization to direction by pharmacist (days)		15 (11–21)	17 (11–21)	14 (12–19)	16 (12–21)
Number of conducted PAIs (n)		4 (1–5)	4 (1–5)	4 (2–5)	4 (2–5)

Notes: Values are presented as median [quartile 1 to quartile 3];

^*P < 0.017,

^**P < 0.003 versus patients with nonmelancholic depression (compared using the Kruskal–Wallis test followed by the Mann–Whitney test, and analyzed for statistical differences using Bonferroni’s correction).

Abbreviations: Overall, overall antidepressant-treated patients; MD, melancholic depression; NMD, nonmelancholic depression; BD, bipolar depression; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin noradrenaline reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; TCA, tricyclic antidepressants; AD, antidepressants.